HER2-Positive Breast Cancer

Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis.

Tucatinib showed improvements in survival in patients with HER2-positive breast cancer.

Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.

The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small.

A new study found a low rate of cancer recurrence at the nipple-areola complex (NAC) in patients with breast cancer who underwent nipple-sparing mastectomy (NSM).

A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.

A new analysis looked at how dose interruptions or reductions of ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes.

A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer.

Researchers looked at the characteristics of breast cancer found in patients under 40 years old.

Researchers compared invasive disease-free survival rates in patients with breast cancer who took nanoparticle albumin-bound (NAB)-paclitaxel compared with those who took solvent-based (sb)-paclitaxel.

A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.

Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer.

Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer.

After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer.

A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.

This phase III trial tested T-DM1 plus pertuzumab vs chemotherapy and dual HER2 blockade in patients with HER2+ breast cancer.

Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine.

Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.

The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.

Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer.

The combination of trastuzumab and paclitaxel 'represents an important step forward in de-escalating therapy' for HER2+ breast cancer.

A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.

Researchers tested whether the use of alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives.

The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer.

An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1–positive, trastuzumab-resistant, advanced HER2+ breast cancer.

The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of < 50%.

The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.

Researchers tested whether combining trastuzumab/paclitaxel with dasatinib would have a high response rate in patients with metastatic HER2+ breast cancer.

The Opti-HER HEART trial examined whether liposomal formulations of chemotherapy agents may reduce cardiac toxicity in HER2+ breast cancer patients.

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.